Connect with us

Mental health

Timing is everything: What AI need to learn about HRT and brain health

Published

on

By Morgan Rose, CNM, WHNP-BC, and Dr Kudesia, triple board-certified in Reproductive Endocrinology & Infertility (REI), Obstetrics & Gynecology, and Lifestyle Medicine

The timing of when women start hormone replacement therapy (HRT) may matter more than we ever understood.

The “critical window” for starting HRT isn’t just relevant to brain health; timing has also been shown to shape cardiovascular outcomes.

Early analyses of the landmark WHI trial missed this nuance, including women long past menopause and obscuring benefits seen in those who begin therapy sooner.

Recent research presented at the American Neurological Association Annual Meeting found that women who began HRT within five years of menopause had a 32 per cent lower risk of developing Alzheimer’s disease.

Yet those who started HRT more than five years after menopause showed higher levels of tau proteins, a hallmark of Alzheimer’s, in their brains.

This “critical window” concept challenges the one-size-fits-all model of menopause care. It suggests that when we start HRT, it can be just as important as whether we start it.

Researchers at Mass General Brigham found similar patterns: women who began HRT near the onset of menopause did not show increased Alzheimer’s risk, while those who experienced early menopause with longer lifetime estrogen deprivation faced a higher risk overall.

Why Timing Matters

Women face roughly a 1 in 5 lifetime risk of Alzheimer’s disease, compared to 1 in 10 for men of the same age. The sharp drop in estrogen during menopause may help explain that gap.

Estrogen supports energy production, blood flow, and inflammation control in the brain functions that wane as levels decline.

The data suggest that initiating HRT earlier (around perimenopause or early menopause) may preserve some of these neuroprotective effects, while starting too late could heighten risk once neurodegenerative changes have already begun.

One meta-analysis showed that HRT begun soon after menopause reduced Alzheimer’s risk by over 40 per cent compared to non-users, while starting after age 60 doubled the risk.

These findings don’t make HRT a blanket prescription; they make it a precision intervention.

The Clinical Nuances AI Must Understand

If AI is going to support menopause care safely and intelligently, it needs to understand the reasons behind the actions.

1. Timing Is a Risk Modifier

“Time since menopause” is not just a demographic; it’s a clinical determinant.

AI systems must understand that the same therapy can carry opposite implications depending on when it’s initiated. 

2. HRT Is Not Monolithic

There are multiple formulations, routes, and combinations.

For women who still have a uterus, adding progesterone helps protect the uterine lining and lowers the risk of endometrial cancer that can occur with estrogen-only therapy.

Topical estrogen, which has much lower absorption into the bloodstream, may be appropriate for perimenopausal women who are still having periods or postmenopausal women with a uterus who need targeted relief of vaginal or urinary symptoms.

For example:

    • Estrogen-alone therapy can raise the risk of endometrial cancer and is typically not recommended for women with a uterus.
    • Topical estrogen, with much lower systemic absorption, may be appropriate for perimenopausal women still having periods.
      These distinctions must be explicitly encoded into AI frameworks to avoid oversimplified or unsafe recommendations.

3. Safety Requires Scope and Referral

Complex topics like HRT timing and neuroprotection should always prompt an automatic follow-up:

“Please consult a menopause specialist or clinician (such as one credentialed through the North American Menopause Society) to discuss the risks, benefits, and best options for you.”

AI logic must mirror how clinicians practice by inviting deeper discussion, not replacing it.

From Symptoms to Systems Thinking

We need to move beyond viewing menopause as a set of symptoms to manage, and instead see it as a neurological and metabolic inflection point in women’s lives.

That means:

  • Bringing conversations about HRT earlier, during perimenopause, when neuroprotective benefits may still be possible.
  • Designing AI systems that recognise context and chronology, not just keywords.
  • Making personalised, evidence-based menopause guidance accessible to every woman by cutting through misinformation and connecting her to trusted care.

The Bigger Picture

For too long, women’s midlife health has been under-researched and under-resourced. The result is a data gap, which can quickly become a bias when encoded into AI.

If we want women’s health AI to truly care, it must be trained on data that understands the complexity of hormonal transitions, not just the vocabulary of them.

Because the difference between “now” and “five years from now” can determine whether a woman ages with clarity or confusion.

AI should know that.

And soon, it will.

Dr Kudesia is nationally recognised for her expertise in fertility awareness, lifestyle, and culinary approaches to reproductive health, and her advocacy for reproductive rights.

Mental health

Cosmetic procedures may become addictive for some women, researchers say

Published

on

Cosmetic procedures may become addiction-like for some women, with low body esteem and problematic social media use linked to higher risk, new research suggests.

A study of 1,614 women aged 25 to 71 found that one in five who had undergone treatments met the threshold for moderate to severe risk of addictive cosmetic procedure use.

Low body esteem and problematic social media use emerged as the strongest risk factors.

Researchers from the Hebrew University of Jerusalem and the Israel Center for Addiction and Mental Health examined what they described as addictive cosmetic procedure use, or ACPU, among Jewish Israeli women.

ACPU refers to repeated cosmetic treatment behaviour that may resemble addiction, including feeling unable to stop, continuing despite negative effects or craving further procedures.

The study was led by Vera Skvirsky alongside Uri Lifshin, Dvora Shmulewitz and Mario Mikulincer, from the department of psychology at the Hebrew University of Jerusalem and the Israel Center for Addiction and Mental Health.

The researchers surveyed women from the general population rather than focusing only on patients at cosmetic clinics.

Among women who had undergone cosmetic procedures, 20 per cent met the threshold for moderate to severe lifetime risk, while more than 15 per cent reported symptoms within the previous year.

Across the full sample, nearly nine per cent of women showed moderate to severe signs of problematic cosmetic procedure use.

The researchers adapted questions based on mental health criteria used to assess substance-related disorders.

Participants were asked whether they had tried unsuccessfully to stop having cosmetic procedures, felt compelled to continue despite negative consequences or experienced cravings linked to treatment.

Previous research has linked cosmetic procedures with body-image concerns and body dysmorphic disorder.

Body dysmorphic disorder is a mental health condition in which a person becomes highly distressed by perceived flaws in their appearance, often flaws that others may not notice.

The new study examined whether repeated cosmetic procedures may, in some cases, resemble a behavioural addiction.

Women with lower body esteem were more likely to report addiction-like patterns, particularly when this was combined with high levels of problematic social media use.

Participants who reported problematic or excessive social media behaviour appeared especially vulnerable when they also felt dissatisfied with their appearance.

The researchers also found smaller links between addictive cosmetic procedure use and lower feminist attitudes, lower attachment security and more negative attitudes towards ageing.

However, those links were less consistent when several factors were analysed together.

The findings come amid a sharp global rise in cosmetic procedures, with international estimates cited by the researchers suggesting interventions increased by around 40 per cent between 2019 and 2023.

The researchers stressed that the study does not suggest cosmetic procedures are inherently harmful.

Instead, they said repeated engagement may, for some people, take on characteristics similar to behavioural addictions already recognised in mental health research.

The researchers said: “Cosmetic procedures have become deeply normalised in many societies, and for many people they may be a positive experience.

“But our findings suggest that for a meaningful minority, the behaviour may begin to resemble other compulsive patterns we see in addiction research, especially when low body esteem and problematic social media use are involved.”

The study was cross-sectional, meaning it captured a single point in time and cannot prove cause and effect.

Researchers said it remains unclear whether problematic social media use contributes to addiction-like cosmetic procedure behaviour, whether treatments influence body image and online engagement, or whether other psychological factors drive both.

Continue Reading

Mental health

SSRIs may lower heat intolerance in women with depression – study

Published

on

SSRIs may help women with depression tolerate extreme heat, with responses more like those without depression, a laboratory study suggests.

Selective serotonin reuptake inhibitors, or SSRIs, are medicines commonly used to treat mental health conditions including depression and anxiety.

Media reports, social media posts and the US Centers for Disease Control and Prevention have suggested SSRIs may increase vulnerability to heat-related illness.

However, researchers found that women with clinical depression who took an SSRI may withstand extreme heat better than those not treating their depression with medication.

The study was carried out by researchers in the Penn State Department of Kinesiology.

Kathleen Fisher, first author of the study, said: “The human body primarily cools itself in two ways, by sweating and by increasing blood flow to the skin so that heat can be released to the environment.

“This study showed that depression interferes with how women’s bodies regulate their temperatures in the heat. Fortunately, SSRIs seem to largely restore the body’s ability to respond to increases in internal temperature.”

The team compared women without depression with those diagnosed with the condition, including women taking different types of antidepressants.

When their body temperatures rose, women with untreated depression were slower to begin sweating and increasing blood flow to the skin.

Their bodies were also less efficient at pumping blood to the skin than those of women without depression and women taking an SSRI.

Depression affects about 10 per cent of the US population and is twice as common among women, the researchers said.

SSRIs, including sertraline and fluoxetine, and serotonin and noradrenaline reuptake inhibitors, or SNRIs, including duloxetine and venlafaxine, are commonly prescribed alongside counselling to treat depression.

Previous research suggests depression disrupts the body’s ability to regulate temperature.

Penn State researchers had previously found that blood vessels dilated less effectively in women with depression. Dilation allows blood vessels to widen, helping more blood reach the skin to cool the body.

Women taking SSRIs showed improved blood vessel dilation similar to that seen among people without depression.

The latest study examined whether the same improvement occurred during heat stress.

Researchers recruited 64 women, almost all in their 20s. The group included 16 without depression and 16 with depression who were not taking medication.

A further 16 had depression and were taking an SSRI, while 16 had depression and were taking an SNRI.

Participants swallowed a small capsule that transmitted their internal body temperature throughout the experiment.

They then wore a suit fitted with tubes that allowed researchers to pump heated water through it.

After 10 minutes of adjusting to water at 91°F, around 33°C, the temperature was raised to 125°F, around 52°C.

The experiment ended when each participant’s internal temperature had risen by 1.8°F, or 1°C. This took an average of 45 minutes.

Researchers also measured skin temperature on the arm, calf, chest and thigh, along with heart rate, blood pressure, blood flow to the skin and sweating.

Professor W Larry Kenney, a study co-author, said: “The water pumped into the suit was 125 F, causing skin temperature to rise to about 100 F.

“As the skin continued to be heated to temperatures similar to sitting in a hot tub, the women’s internal temperature continued to rise.”

Women with untreated depression were slower to begin sweating and increasing blood flow to the skin than women without depression.

When blood flow to the skin increased, it was less efficient. Despite beginning to sweat later, women with untreated depression did not sweat less overall.

Women taking SSRIs responded to heat in a similar way to women without depression.

By contrast, women taking SNRIs responded similarly to those with untreated depression. SSRIs therefore normalised responses to heat stress, while SNRIs did not.

Researchers found no differences in blood pressure between the four groups.

Fisher said: “Up until now, there has been very little data on how depression or any of these classes of antidepressive drugs affect people’s responses to heat stress.

“This study took the first step toward understanding how women with depression, whether taking medications or not, may respond to extreme heat.”

Kenney said the findings challenged common beliefs that SSRIs increase vulnerability to heat.

He said: “In prior studies, my collaborators and I have identified how several factors, especially age, sex, and activity level, contribute to risk from extreme heat.

“Additionally, there has been widespread concern that many medications contribute to heat vulnerability, but the research evidence behind the risks of many medicines is often thin or nonexistent.

“Both physicians and people taking SSRIs should be aware that these medications do not seem to contribute to heat vulnerability. Rather, SSRIs improve heat tolerance in depression.”

Continue Reading

Insight

The danger of ‘efficiency culture’ in women’s mental tech

Published

on

By Somayeh McKian, a member of the clinical advisory board of Vea, the AI-powered mental health journal app

The danger of efficiency culture in women’s mental tech is that we are inadvertently optimizing the very patterns that drive our collective burnout.

When we look at the explosive growth of the femtech sector, the dominant narrative remains focused on speed, tracking, and passive compliance.

We build apps that treat a woman’s emotional state like a broken supply chain or a medical deficit that needs to be optimised, streamlined, or forced into submission.

But true psychological resilience cannot be quantified by a simple mood slider or an algorithmic checkmark.

As a psychotherapist and gender studies scholar, my research into the lived experiences of women, particularly how cultural mandates and bodily surveillance are pathologised, reveals a deep-seated form of suffering.

When women constantly say “yes” while meaning “no,” or ignore a chronically depleted body to maintain a rigid role, they are living out what I call an “inkless life.”

It is a blank manuscript in which their physical and emotional existence has been entirely authored by external critics, medical charts, and the “Discourse of the Other.”

They aren’t suffering from an efficiency problem; they have been stripped of the agency to author their own skin.

If femtech platforms simply digitise these rigid, externalised “shoulds,” they risk becoming high-tech tools of compliance rather than portals of liberation.

The investment community and health tech innovators need to realise that the next frontier of mental health tech isn’t about managing symptoms on the fly; it is about existential archaeology.

We must build digital spaces that serve as a “corporeal pen,” transforming self-reflection from a passive hobby into a defiant, existential act.

True innovation lies in helping women find the meaning, the latent metaphors, and the unique tasks already written into their struggles and transforming inherited pain into a human achievement.

This is exactly the structural paradigm shift we are anchoring at Véa. Instead of building superficial tracking logs, our architecture treats life as a manuscript.

We design clinical narrative journeys that help women decode where their internal boundary scripts were written, recognize how somatic depletion is a truth-teller, and wield phrases like “stop it” not as external policing, but as internal, defiant boundaries.

If we want to build a sustainable ecosystem for women’s health, we must stop funding platforms that merely help women endure their exhaustion more efficiently.

In the intersection of meaningful life and technology, we look at the human spirit not by its current restrictions but by its latent potential for change.

It is time to back technologies that give the fluent soul a sharp new set of instruments to rewrite its own narrative.

Somayeh McKian is a certified psychotherapist, in-training logotherapist, gender studies scholar, published author and part of Véa’s clinical advisory board.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.